Nektar Therapeutics (NKTR) News
Filter NKTR News Items
NKTR News Results
|Loading, please wait...|
NKTR News Highlights
- For NKTR, its 30 day story count is now at 8.
- Over the past 10 days, the trend for NKTR's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
Latest NKTR News From Around the Web
Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.
Leerink Partners Stick to Their Hold Rating for Nektar Therapeutics
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03, MarketWatch Earnings reports. Nektar Therapeutics had a negative net margin of 269.05% and a negative return on equity of 30.74%. During the same quarter in the […]
Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost 1.5% to close at $22.44 on Feb. 25. Nektar (NKTR) incurred a loss of $0.65 per share in 4Q, compared to the $0.68 loss per share estimated by analysts. Total sales generated in the quarter amounted to $23.5 million, falling short of analysts’ expectations of $30.01 million. The company’s research and development expenses were $102.7 million in the quarter, down 7% year-over-year. (See Nektar stock analysis on TipRanks) Nektar CEO Howard W.
Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.
The analysts covering Nektar Therapeutics ( NASDAQ:NKTR ) delivered a dose of negativity to shareholders today, by...
Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics Fourth Quarter 2020 Financial Results. With us on the call are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Chief of Research and Development; and Dr. Brian Kotzin, our Interim Chief Medical Officer and Head of Development.
Nektar Therapeutics Will stock surge before Earnings results? Stock market Insights & financial analysis
Nektar Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Mizuho Securities Stick to Their Buy Rating for Nektar Therapeutics
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDA...